

## PATENT APPLICATION TRANSMITTAL LETTER

(Small Entity)

Docket No.

MT-0003

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

SSEL ET AL.

For:

## COMPOSITIONS AND METHODS FOR WEIGHT REDUCTION

Enclosed are:

- ☒ Certificate of Mailing with Express Mail Mailing Label No. EL045264339US
- ☐ sheets of drawings.
- ☐ A certified copy of a application.
- ☒ Declaration ☐ Signed. ☒ Unsigned.
- ☒ Power of Attorney
- ☐ Information Disclosure Statement
- ☐ Preliminary Amendment
- ☒ ONE Verified Statement(s) to Establish Small Entity Status Under 37 C.F.R. 1.9 and 1.27.
- ☒ Other: RETURN POST CARD

## CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	3	- 20 =	0	x \$9.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$39.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$380.00
TOTAL FILING FEE					\$380.00

- ☒ A check in the amount of \$380.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 12-1086 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: December 4, 1998

*Jane Massey Licata*

Signature

JANE MASSEY LICATA  
Law Offices of Jane Massey Licata  
66 E. Main Street  
Marlton, NJ 08053  
Tel: (609) 810-1515  
Fax: (609) 810-1454

CC:

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (c)) - SMALL BUSINESS CONCERN**

Docket No.  
MT-0003

Serial No.  
**NOT ASSIGNED YET**

Filing Date  
**HEREWITH**

Patent No.  
**NOT ASSIGNED YET**

Issue Date

Applicant/ **HESSEL ET AL.**  
Patentee:

Invention:

**COMPOSITIONS AND METHODS FOR WEIGHT REDUCTION**

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: **NATURAL MEDICO TECH A/S**

ADDRESS OF CONCERN: **HERSTEDVANG 7B, 2620 ALBERTSLUND, DENMARK**

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: THEA OLESEN

TITLE OF PERSON SIGNING \_\_\_\_\_

OTHER THAN OWNER: Secretary, Natural Medico Tech A/S

ADDRESS OF PERSON SIGNING: Herstedvang 7B  
Albertslund, Denmark

SIGNATURE: \_\_\_\_\_

DATE: \_\_\_\_\_

1<sup>st</sup> December 1998

## COMPOSITIONS AND METHODS FOR WEIGHT REDUCTION

## Background of the Invention

Obesity is a condition that affects millions of Americans. Recent statistics show that when obesity is defined  
5 as a 20% excess over desirable weight, 20-30% of adult men and 30-40% of adult women are obese. Even mild obesity increases the risk for premature death, diabetes, hypertension, atherosclerosis, gallbladder disease, and even some forms of cancer (Olefsky, J.M. 1994, *Harrison's Principles of Internal*  
10 *Medicine*, 446-452). Therefore, effective methods for weight reduction are constantly being sought.

Although there are many different treatment regimens in use today that can produce a short term or temporary weight loss, most are associated with a rapid increase in weight once  
15 treatment is terminated. Caloric restriction is the main goal of most weight reduction treatment regimens. The basic principle is that if intake of food is less than energy expenditure, stored calories will be consumed, mainly in the form of fat. However, once the diet regimen is broken, weight  
20 is quickly regained.

Other treatment regimens are based on the principle of increasing metabolism. By increasing metabolism, calories are burned thereby decreasing body weight. However, these treatments often have side effects, particularly those  
25 involving use of non-prescription and prescription drug products. Further, these treatments also often result in rapid

weight increases once treatment is terminated, unless modification of behavior that led to weight gain is undertaken. In the case of nutritional supplement regimens, poor taste is often a problem despite addition of taste-improving substances  
5 to the product.

Weight reduction has also been attempted using surgical intervention wherein the size of the stomach is reduced so that a feeling of gastric fullness is produced, resulting in a decrease in appetite and food intake. One such method is  
10 placement of a mechanical device such as an inflatable balloon into the stomach. However, such invasive methods are not routinely used.

The use of herbal plant extracts to control weight has also been described. For example, the herb Guarana (*Paullinia  
15 cupana*, *P. sorbolis*) which contains a high concentration of the active ingredient caffeine has been incorporated into slimming products (Hurel, J.-P., 1993, FR 2 712 191-A1). Caffeine is recognized to have pharmacological activity as a central nervous system stimulant and is a major constituent in many  
20 weight-reducing products for its ability to increase metabolic rate. However, use of such a product alone has only a temporary effect, with weight gain seen immediately upon cessation of treatment. Similarly, Prunet (FR 2 687 548 A1) describes the use of Guarana as a nutritional supplement in  
25 short term weight reduction. Finally, Primez (Belgium Patent 100593A7) describes a phyto-active mixture referred to as Lycopodium which contains Guarana and other plant extracts including *Scillia maritime*, *Ephedra vulgaris*, and *Betula alba* which may be ingested, applied as a cream or lotion, or  
30 injected to produce weight loss. It is suggested that administration of Lycopodium slows gastric draining while improving intestinal transit and evacuation of the intestines. However, no clinical data is provided to support this suggestion.

35 It has now been found that a combination of selected herbal extracts wherein at least one of the extracts contains

caffeine and at least one of the extracts controls gastric emptying is capable of producing weight loss.

### Summary of the Invention

An object of the present invention is to provide a composition comprising a combination of selected herbal extracts that produces weight loss in a patient through inhibition of gastric emptying and an increase in metabolic rate in the patient.

Another object of the present invention is to provide a method of reducing weight in patients which comprises administering to the patient a composition comprising a combination of selected herbal extracts that inhibits gastric emptying and increases metabolic rate in the patient.

### Detailed Description of the Invention

The periodic discharge of food from the stomach into the small intestine, also referred to as gastric emptying, is caused by contraction of the muscles in the wall of the stomach. These muscles are innervated by the cranial vagus nerves, which stimulate contraction of the gastric muscles and allow sphincter between the stomach and the duodenum to open. The present invention relates to a composition comprising a combination of selected herbal extracts wherein at least one of the herbal extracts inhibits gastric emptying. Because nutritional uptake through the mucosal lining of the stomach is extremely low, the extended retention period in the stomach of food resulting from these compositions does not have any discernable effect on the eventual uptake of nutrients. However, inhibition of gastric emptying results in a decreased appetite thereby decreasing food intake. The compositions of the present invention further comprise at least one herbal extract capable of modifying metabolic rate through the presence of significant concentrations of caffeine. Increasing the metabolic rate of a patient while inhibiting gastric emptying in the patient by administering a composition of the present invention results in weight loss. Active ingredients

extracted from the plants are used as a natural nutritional supplement in such a way to control the uptake of nutrients by delaying gastric emptying. At the same time plant extracts are incorporated which are known to promote weight loss by increasing metabolism. The composition of the present invention thus provides a combination of selected herbal extracts which has been shown to be effective in producing weight loss in clinical studies.

Herbal plant extracts that have been assessed and found to be suitable for selection and incorporation into a composition of the present invention for achieving a controlled and durable weight loss include Buchu (*Barosma betulina*, *B. crenulata*, *B. serratifolia*), Vervain (*Verbena officinales*, *V. jamaicensis*, *V. lappulacae*, *V. hesitate*, *V. urticifolia*, *V. Sinuata*), Damiana (*Tumera diffusa* var. *aphrodisiaca*, *T. opifera*, *T. ulmifoliei*), Guarana (*Paullinia cupana*, *P. sorbalis*), Paraguay (*Ilex paraguarensis*, *I. vomitoria*, *I. Dahoon*), Kola (*Cola nitida*, *C. vera*), and Ginseng (*Panax ginseng*, *P. quinquefolius* L.). The active ingredients of each herb are listed in Table 1:

**TABLE 1**  
**Active Ingredients of Selected Herbs**

Herb	Active Ingredient(s)
Buchu	volatile oil of buchu camphor, diosphenol
Vervain	verbanaline (glycoside, adenosine, essential oils, tannin, livertin, emulin
Damiana	ethers, terpenes (a-pinene, cineol, p-cymol, sesquiterpenes), resin, bitter pineapple, tannin, caoutchouc, albuminoids, starch, arbutin

Guarana	caffeine, other xanthines (tetramethylxanthine, theobromine, theophylline, tannin)
Paraguay	caffeine
Kola	caffeine
Ginseng	triterpenoid saponin

5 As will be obvious to those of skill in the art, other herbal  
extracts having these active ingredients can also be selected  
for use in a composition of the present invention. Herbal  
extracts for combination into a composition of the present  
invention are obtained in accordance with methods well known  
10 and routine to those of skill in the art.

A composition of the present invention comprising a  
combination of selected herbal extracts was administered to  
patients in a double blind controlled clinical trial. The  
combination tested included Guarana, Damiana, and Paraguay.  
15 Guarana is a dough from the seeds of *Paullinia sorbolis*, which  
grows in Brazil and Venezuela. It contains 3-6% caffeine, 5-  
8.5% tannin, 7.8% resins, 2-3% fat, 0.06% saponin, 5-6% starch,  
and 1.5% coloring agents. Paraguay is an extract of *Ilex*  
*paraguensis* which grows in Brazil, Argentina, and Paraguay. It  
20 contains 1-1.5% caffeine, 4-10% tannin, and 3% resins and fat.  
Damiana is obtained from the leaves of the plant *Turnera*  
*diffusa* var. *aphrodisiaca* from California, Mexico, Brazil, and  
Bolivia and contains ethereal oils, resins, and tannin. These  
extracts were obtained as powders. The components were mixed  
25 and prepared as capsules. Each capsule contained 95 mg  
Guarana, 112 mg Paraguay, and 36 mg Damiana extract. The  
subjects for the study were 20 otherwise healthy subjects,  
complaining of light-moderate overweight with a body mass index  
between 25 and 30 kg/m<sup>2</sup>. None of the subjects were taking any  
30 drug or dietary supplement at the time of the study. All were  
briefed on the protocol and gave consent to the trial.

In this double blind placebo controlled trial, the  
subjects were randomized into two groups A and B. Group A was



supplied with test capsules and group B with placebo (water coated capsules containing lactose) for 20 days. The participants took three meals a day and were instructed to take 2 capsules with a large glass of water (250 ml) from 10-15 minutes before each meal. Using a stopwatch, each subject then recorded the time elapsing to perception of gastric fullness. Subjects also were asked to note any side effects. Three days after the end of the first 20 day trial, the procedure was repeated with the test capsules now being given to the group B subjects and the placebo capsules to group A subjects. All subjects completed the test.

The subjects in group B, receiving the placebo capsules in the first period reported an average time for perception of fullness of 60 minutes (range 55-65 minutes). In the second period, when taking the test combination product, the average time for perception of fullness in this same group was 36 minutes (range 33-41 minutes). These average values were statistically different ( $p < 0.01$ ). Therefore, the study showed that treatment with the herbal extract combination produced statistically significant decreases in the time to perception of fullness.

The rate of gastric emptying was assessed by scintigraphy. Three volunteer male subjects with no gastrointestinal illness or intake of medicinal drugs took part in the study. They were given a meal consisting of 18 g peas, 100 g dried potatoes, and 200 ml of water containing 16-20 Mbc <sup>113</sup>Indium-DPTA. The subjects were fasting before the test and the meal was consumed in five minutes. The test was conducted with the subjects in a semi-upright position with a gamma camera placed in front. The time course of radioactivity in the stomach was determined by measuring the radioactivity in an appropriate region of interest every minute over 90 minutes. The test was repeated after each subject had taken three capsules of the drug combination three times daily and three capsules having been mixed with the food. Results showed that the rate of gastric emptying was significantly decreased in the three subjects after taking the herbal extract combination

product. Halving times of gastric emptying were 49, 31, and 32 minutes after taking the test product and 61, 50, and 49 minutes, respectively, after taking the placebo.

Ultrasound examination of the stomach was also employed using a 3.5 MHz curved array transducer and an Aloka 630 standard unit employing a modification of the techniques by Holt et al. (Holt, S. et al., 1980, *Gut*, 1:597-601) and Bateman and Whittingham (Bateman, D.N. and T.A. Whittingham, 1982, *Gut*, 23:524-527). Continuous scans were performed switching the transducer between two alternate projections, one oblique upward view with the transducer positioned under the left curvature allowing the gastric fundus, corpus, and antrum to be inspected or a transverse view across the epigastrium with a slight upward direction viewing the antrum pylorus and the duodenal bulb. All examinations were recorded on videotape and still pictures were taken every five minutes. This technique was used in a further double-blind crossover study on 7 healthy normal volunteers with no history of gastrointestinal diseases. Each volunteer had 2 to 8 examinations with the test capsules or placebo capsules (lactose), followed by 20 ml of apple juice and 15 minutes later with 400 ml of apple juice. The projections gave clear visual estimation of the volume of the stomach. Gastric emptying time (GET) was defined as the elapsed time between ingestion of the 400 ml of apple juice and the time when the fundus and corpus of the stomas were completely empty. The results were noted immediately and controlled by playback of the videotapes. After termination of the study the codes were broken and GET values were compared by an independent analyst. The results showed that there was a considerable variation among the subjects and within the same subject. However, even with this variability, a delaying effect on gastric emptying was associated with administration of the herbal extract combination product, an effect that was evident in all seven subjects and is shown in Table 2.

TABLE 2		
Results of the Ultrasound Study: Comparison of Gastric Emptying Time (GET)		
Subject	Placebo GET (minutes)	Herbal Extract GET (minutes)
A	37.0	63.5
B	47.5	70.0
E	45.5	80.0
M	29.0	44.5
H	31.0	46.0
J	34.0	39.0
T	44.0	60.0
Mean Value	31.8	57.6

The effect on body weight of 10 days treatment with the test compound and placebo was recorded in a double blind pilot study of 44 healthy subjects was also determined. None of the subjects took any drugs and none were on a specific diet. The patients were instructed to take three capsules (test compounds or placebo) with a large glass of water 15 minutes before main meals and also to take care to not change their normal food habits. They also were asked to note side effects. The subjects were weighed before and after the period of 10 days. Twenty-two patients with a BMI range 25.1 to 29.5 took the test capsules and 22 patients with a BMI of 24.9 to 29.0 received the placebo. Results showed that of the 22 subjects who received the placebo, there was a mean decrease in body weight of 0.3 kg (SEM = 0.03) while in the 22 subjects who received the herbal extract product, there was a mean decrease of 0.8 kg (SEM = 0.05).

The effect on body weight of 45 days of treatment with the herb combination and placebo was also studied in a double blind randomized crossover study of 47 patients. These subjects were healthy but overweight (BMI range 25.8 to 30.4). They did not take any medicinal drug or diet before or during

the study. All 47 were between the ages of 20 and 60 years of age and gave full consent. In the study, the 24 subjects in group A received the test capsules in the first period. This group showed a mean decrease in body weight of 5.1 kg (SEM = 5 0.5) while taking the herbal extract product. In contrast, the placebo group in the first period had a mean decrease in body weight of only 0.5 kg (SEM = 0.08).

A recording of weight maintenance over 12 months after an initial weight loss was made to assess the long term 10 effectiveness of the treatment. Twenty-two of the subjects from the various studies above who had lost an average of 3.6 kg were invited to take part. Each subject received a month's supply of the test drug each month they returned to the study center for weight measurement.

15 No side effects were noted in any of the clinical tests. The results of these experiments demonstrate the effectiveness of the herbal extract combination in weight reduction in humans.

What is claimed is:

1. A composition which produces weight loss in a patient comprising a combination of selected herbal extracts wherein said combination comprises at least one herbal extract capable of inhibiting gastric emptying and one herbal extract which increases metabolic rate in a patient.

2. The composition of claim 1 wherein the combination of selected herbal extracts comprises Guarana, Damiana, and Paraguay.

10           3.    A method of reducing weight in a patient comprising  
administering to a patient a composition of claim 1 so that  
gastric emptying is inhibited and metabolic rate is increased  
in the patient.

**ABSTRACT**

Compositions containing a combination of selected herbal plant extracts that inhibit gastric emptying time and increase metabolic rate are provided which are useful in reducing weight  
5 in patients.

Docket No.  
MT-0003

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### COMPOSITIONS AND METHODS FOR WEIGHT REDUCTION

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as United States Application No. or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
_____	_____	_____	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/067,706

December 8, 1997

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

JANE MASSEY LICATA REG.NO. 32,257  
KATHLEEN A. TYRRELL REG. NO. 38,350

of the firm:

Law Offices of Jane Massey Licata  
66 E. Main Street  
Marlton, NJ 08053

Send Correspondence to: Jane Massey Licata  
Law Offices of Jane Massey Licata  
66 E. Main Street  
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*  
Jane Massey Licata Tel: (609) 810-1515 Fax: (609) 810-1454

Full name of sole or first inventor <b>Lasse Lief Hessel</b>	
Sole or first inventor's signature	Date
Residence <b>Svendborg, Denmark</b>	
Citizenship <b>Danish National</b>	
Post Office Address <b>Rantzausmindevej 111</b>	
<b>DK-5700 Svendborg, Denmark</b>	

Full name of second inventor, if any <b>Jorgen Scherning Lundsgaard</b>	
Second inventor's signature	Date
Residence <b>Svendborg, Denmark</b>	
Citizenship <b>Danish National</b>	
Post Office Address <b>Otte Rudsvej 1</b>	
<b>DK-5700 Svendborg, Denmark</b>	